7 citations
,
July 1995 in “PubMed” Finasteride, a drug that changes testosterone to a different hormone, was studied and its effects over time were modeled successfully.
15 citations
,
June 1995 in “The Journal of Clinical Endocrinology and Metabolism” This study found that finasteride significantly reduced dihydrotestosterone levels but did not provide clear evidence of impaired libido or erectile function compared to placebo in men.
15 citations
,
June 1995 in “The American Journal of the Medical Sciences” This study describes a case where finasteride treatment for benign prostatic hypertrophy was associated with gynecomastia in a 62-year-old man, which resolved after the drug was discontinued.
45 citations
,
August 1994 in “Journal of Chromatography B: Biomedical Sciences and Applications” Method detects finasteride in plasma and semen with high sensitivity and accuracy.
5 citations
,
July 1994 in “PubMed” This study found that finasteride administered for 28 days had no significant effect on adrenal steroidogenesis in healthy men, aside from inhibiting androstenedione metabolism.
9 citations
,
October 1993 in “The Journal of Clinical Pharmacology” Finasteride doesn't affect antipyrine metabolism, so interactions with cytochrome P-450 enzyme drugs are unlikely.
86 citations
,
July 1993 in “Drugs” Finasteride treats enlarged prostate, shrinks it, improves urination, but may cause sexual dysfunction and isn't for women or children.
70 citations
,
June 1993 in “Biochemistry” This study found that the binding of finasteride to the enzyme 5a-reductase occurs at a slower rate than previously assumed, complicating the estimation of its real inhibitory constant.
12 citations
,
January 1993 in “PubMed” This review discusses the pharmacology and clinical use of finasteride for benign prostatic hyperplasia and reports its effectiveness in reducing prostate size and symptoms, though success varies among patients.
1040 citations
,
October 1992 in “The New England Journal of Medicine” In this study, 5 mg of finasteride per day significantly improved urinary symptoms and reduced prostate volume in men with benign prostatic hyperplasia, but increased the risk of sexual dysfunction.
10 citations
,
October 1992 in “Hormone and Metabolic Research” Finasteride safely lowers DHT levels without affecting hormone levels, helping with conditions like enlarged prostate, acne, and hair loss.
17 citations
,
March 1992 in “PubMed” This study reports that finasteride administered orally in humans is mainly metabolized through oxidative pathways, with most of the dose excreted as metabolites, primarily in the feces.
19 citations
,
May 1991 in “Journal of Chromatography B: Biomedical Sciences and Applications” This study developed and validated an HPLC method for detecting a novel 5α-reductase inhibitor in human plasma, supporting its pharmacokinetic evaluation at low doses.
211 citations
,
November 1990 in “The Journal of Steroid Biochemistry and Molecular Biology” Finasteride effectively treats BPH, but needs more trials to understand potential.
147 citations
,
April 1990 in “The Journal of Clinical Endocrinology and Metabolism” This study found that finasteride significantly suppresses serum dihydrotestosterone levels at all tested doses in normal male volunteers without significant adverse effects.
